Analysis for Xtrackers MSCI Emerging Markets ETF
Analysis summary
Xtrackers MSCI Emerging Markets ETF (XMME.DE) currently has a total score of 58 points, placing it in the neutral range. The score is made up of Performance (53), Stability (62) and Trend (67).
Performance scores 53 points (neutral). Key strength: 1Y return at 24.1 %. Weaker metric: 5Y return at 32.3 %. This points to a sharper upswing more recently.
Stability scores 62 points (strong). Best-ranked metric: max drawdown (5Y) at -26.6 %. Main drag: Sharpe ratio (90d) at 0.55. Higher Stability points are better and typically reflect calmer swings and smaller drawdowns—but prices can still fall.
Trend scores 67 points (strong). Key strength: Price is about 16.2 % above SMA200. Even the weakest metric remains solid in absolute terms: trend strength at 0.70. That often means the move is strong, but not perfectly steady.
Overall, the score is shaped most by Trend; Performance trails and dampens the total. On a metric level, max drawdown (5Y) stands out, while 5Y return lags.
(Historical evaluation, not investment advice.)
Metrics
Stability
FAQ
- What investor type does Xtrackers MSCI Emerging Markets ETF fit best in FoxScore?
- Xtrackers MSCI Emerging Markets ETF fits a trend/momentum-oriented investor type in FoxScore: trend is clearly the strongest sub-score. This can be useful if you follow trends — but pay close attention to stability (drawdowns/volatility) because trend signals can flip quickly.
- How meaningful is the available history for Xtrackers MSCI Emerging Markets ETF?
- Xtrackers MSCI Emerging Markets ETF currently has about 8.7 years of price history since it started trading. That’s a solid base to interpret returns, drawdowns and trend behavior since launch — earlier market crises happened before the asset existed and are therefore not part of its history.
- What is FoxScore good for — and what is it not for?
- FoxScore is an analysis and comparison tool: it helps you sort assets quickly, compare profiles and spot strengths/weaknesses. It’s not a substitute for your own research or fundamental analysis, and it’s not a buy/sell recommendation.